Chardan Capital Reaffirms Buy Rating for SONNET BioTherapeutics (NASDAQ:SONN)

Chardan Capital restated their buy rating on shares of SONNET BioTherapeutics (NASDAQ:SONN) in a report released on Thursday morning, TipRanks reports. Chardan Capital currently has a $7.00 target price on the stock.

Shares of NASDAQ:SONN opened at $3.82 on Thursday. SONNET BioTherapeutics has a 52-week low of $3.62 and a 52-week high of $54.60. The company has a debt-to-equity ratio of 3.10, a quick ratio of 0.08 and a current ratio of 0.10.

SONNET BioTherapeutics (NASDAQ:SONN) last announced its quarterly earnings data on Monday, May 18th. The company reported ($0.05) earnings per share (EPS) for the quarter. The firm had revenue of $0.01 million during the quarter. SONNET BioTherapeutics had a negative return on equity of 1,025.86% and a negative net margin of 82.24%. As a group, analysts predict that SONNET BioTherapeutics will post -2.96 EPS for the current year.

About SONNET BioTherapeutics

SONNET BioTherapeutics, Inc is a biotechnology company that engages in development of bi and tri functional therapies that can simulate or block immune-modulating targets to control cancer. The company uses albumin binding single chain antibody fragment (scFv) for delivery of recombinant human-cytokines (rH-cytokines) and other validated targets.

Recommended Story: Gross Domestic Product (GDP)

Receive News & Ratings for SONNET BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SONNET BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.